Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Former Fumapharm shareholders get $761mm cash for selling earn-out interest to Royalty Pharma; $510mm added

Executive Summary

In exchange for $761mm in cash, Royalty Partners (operates by taking on royalty interests in biopharma products) has acquired from the former owners of Fumapharm the future earn-outs they were entitled to under Biogen Idec’s 2006 $220mm takeover of Fumapharm. The earn-outs--consisting of $315mm in regulatory- and sales-based achievements--are predominantly tied to US or EU approval ($15mm) and commercialization ($300mm) of BG12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis. Royalty Pharma is also acquiring an interest in the earn-out for Fumaderm (fumaric acid esters), an approved drug in Germany for moderate-to-severe plaque psoriasis.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Other

Related Companies